Gendron Denis J, Hamblin Michael R
1 Invitalize, Inc. Kitchener, Ontario, Canada.
2 Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts.
Photobiomodul Photomed Laser Surg. 2019 Jul;37(7):408-420. doi: 10.1089/photob.2018.4597.
Musculoskeletal disorders caused by osteoarthritis (MSDs/OA) are a growing problem in the modern industrialized society in Canada. Overall aging of the general population and a progressive lack of exercise contribute to this alarming increase. Moreover, a range of chronic conditions including cardiovascular and mental diseases show significantly higher comorbidity with MSDs/OA. Conventional medical treatment for MSDs/OA includes nonsteroidal anti-inflammatory drugs and opiate pain killers. These drugs have major drawbacks such as a relative lack of efficacy, potential for addiction, and even death (Vioxx scandal). Photobiomodulation (PBM) was discovered over 50 years ago but has still not attained widespread acceptance by the medical community. This is partly due to uncertainty about the precise molecular mechanisms of action and a bewildering array of different wavelengths and dosimetric parameters employed in reported studies. The goal of this review was to survey literature reports of PBM, also known as low-level laser therapy used for treatment of MSDs/OA, concentrating on the growth over time, different wavelengths employed, and application to different joints. We searched the PubMed database for publication of study on PBM to treat the most common joints. We show that the field of PBM to treat MSDs/OA is expanding exponentially over the past 20 years. A trend has emerged over time for more power to achieve better effective treatments, and the understanding of the physiological effect of safe parameters has improved. There is, however, no consensus on the best set of parameters to treat a specific patient indication. Finally, we highlight gaps in our knowledge and the barriers to further clinical trials. We suggest that the growing body of evidence indicating efficacy, and the almost total lack of side effects, should encourage continued clinical research to support clinical applications where better rehabilitation treatments are much needed.
骨关节炎引发的肌肉骨骼疾病(MSDs/OA)在加拿大现代工业化社会中是一个日益严重的问题。总体人口老龄化以及运动量的逐渐减少导致了这一令人担忧的增长趋势。此外,包括心血管疾病和精神疾病在内的一系列慢性疾病与MSDs/OA的共病率显著更高。MSDs/OA的传统医学治疗包括非甾体抗炎药和阿片类止痛药。这些药物存在主要缺点,如相对疗效不足、成瘾可能性甚至死亡(万络丑闻)。光生物调节(PBM)在50多年前就已被发现,但仍未被医学界广泛接受。部分原因是其确切分子作用机制尚不确定,且报告研究中使用的不同波长和剂量参数令人困惑。本综述的目的是调查PBM(也称为用于治疗MSDs/OA的低强度激光疗法)的文献报道,重点关注其随时间的发展、使用的不同波长以及在不同关节的应用。我们在PubMed数据库中搜索了关于PBM治疗最常见关节的研究出版物。我们表明,在过去20年中,PBM治疗MSDs/OA的领域呈指数级扩展。随着时间的推移,出现了一种趋势,即更高的功率能实现更好的有效治疗,并且对安全参数的生理效应的理解有所改善。然而,对于治疗特定患者适应症的最佳参数集尚无共识。最后,我们强调了知识空白和进一步开展临床试验的障碍。我们建议,越来越多表明其有效性且几乎完全没有副作用的证据,应鼓励继续进行临床研究,以支持在急需更好康复治疗的临床应用。